The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

The Hawkeye actress' compliment comes after Allen surpassed NFL legend Russell Wilson for the most wins by a quarterback in ...

Hailee Steinfeld is teaming up with Novartis to raise awareness about breast cancer with an empowering Super Bowl 59 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/103.DZznz2u5.js ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.